Preventive ceftriaxone in patients at high risk of stroke-associated pneumonia. A post-hoc analysis of the PASS trial.

PLoS One

Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Published: January 2023

Background: Infections complicate the acute phase of stroke in one third of patients and especially pneumonia is associated with increased risk of death or dependency. In randomized trials of stroke patients, preventive antibiotics reduced overall infections, but did not reduce pneumonia or improve outcome. This may be explained by broad selection criteria, including many patients with a low risk of pneumonia. To assess the potential of selection of patients at high risk of pneumonia, we performed a post-hoc analysis in the Preventive Antibiotics in Stroke Study (PASS).

Methods: PASS was a multicentre phase 3 trial in acute stroke patients who were randomized to preventive ceftriaxone for four days within 24 hours or standard care. For this analysis patients were divided based on the ISAN risk score for pneumonia as follows: low (0-6), medium (7-14) and high (15-21). Primary outcomes were pneumonia rate during admission as judged by the treating physician, and by an independent committee; secondary outcomes were overall infections and unfavorable outcome (modified Rankin Scale ≥3). We adjusted with multivariable regression for possible confounders: age, stroke subtype and severity, pre-stroke dependency and diabetes.

Results: Pneumonia occurred more frequently in higher risk groups (25.7% (high), 9.0% (medium) 1.5%, (low)). The absolute difference in pneumonia rate between patients treated with ceftriaxone or standard care increased with the ISAN score (low: 0.5%, medium: 1.2%, high: 10.1%). After adjustment ceftriaxone reduced overall infections in the low and medium groups, not in the high-risk group. There was a trend towards reduction of pneumonia as judged by the committee (3.7% vs 13.6%, aOR = 0.164, p = 0.063) in the high-risk group.

Conclusions: This post-hoc analysis of PASS confirmed higher rates of pneumonia with higher ISAN scores, and suggests that in acute stroke patients with an ISAN score of ≥15, preventive ceftriaxone for four days may reduce pneumonia rate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803205PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279700PLOS

Publication Analysis

Top Keywords

preventive ceftriaxone
12
pneumonia
12
post-hoc analysis
12
stroke patients
12
pneumonia rate
12
patients
9
patients high
8
high risk
8
analysis pass
8
preventive antibiotics
8

Similar Publications

An Unexpected Case of Generalized Tetanus.

Cureus

December 2024

Intensive Care Unit, Unidade Local de Saúde da Região de Aveiro, Aveiro, PRT.

Tetanus is a disease of the nervous system caused by a toxin produced by , an anaerobe found in high concentrations in the soil. The occurrence of tetanus is related to contaminated traumatic wounds, and most patients have had some failure in their immunization. However, there are rare case reports of generalized tetanus in patients with proper vaccination schemes who failed to receive appropriate prophylaxis after high-risk exposure.

View Article and Find Full Text PDF

Antibiotics remain the most effective option for combating infections. However, the situation has shifted from ideal to concerning, as bacterial resistance to antibiotics is increasing in both prevalence and strength. : This study explores the synergistic/antagonistic potential of combining antibiotic and photodynamic therapy (PDT) against .

View Article and Find Full Text PDF

Background And Aims: Although beneficial in reducing the risk of bacterial infections in patients with advanced decompensated cirrhosis after upper gastrointestinal (GI) bleed, the utility of prophylactic antibiotics in those with Child-Pugh A cirrhosis is not known. We studied if prophylactic antibiotics can be withheld in this cohort.

Methods: This was a single-centre, open-label randomised-controlled-trial with non-inferiority design.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research has classified a specific bacterial strain as low-risk for producing a certain enzyme affecting antibiotic efficacy, but there is limited data on how antibiotic choices impact patient outcomes in bacteremia.
  • This study focused on comparing clinical outcomes between patients treated with AmpC-directed β-lactam therapy and narrower spectrum therapies for ceftriaxone-susceptible bacteremia, reviewing records over an 8-year period from seven hospitals.
  • Results indicated that while carbapenem therapy showed trends toward lower mortality and longer treatment duration, these differences weren't statistically significant, emphasizing the need for proper antibiotic stewardship to avoid the development of drug-resistant bacteria.
View Article and Find Full Text PDF

Background: Pertussis is a highly contagious respiratory disease caused by (BP). Despite global control of pertussis cases through the Expanded Programme on Immunization (EPI), there has been a significant increase in the incidence of pertussis in recent years, characterized by a "resurgence" in developed countries with high immunization rates as well as a comparable reemergence in certain areas of China. We aim to explore the genotypes and antimicrobial susceptibility of circulating BP from children in Hebei.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!